After short-term administration of Xymedon (410 mg/kg, 5 days of treatment), we observed increases in tumor necrosis area (not significant), CD3 and CD8 cell counts (total and killer T-cells, respectively) (not significant), and CD20 cells (B-lymphocytes) (significant). This evidence concerns the gene CD8A and neoplasm.